Immune cell therapy takes on rare Muscle-Weakening disease
Disease control
Ongoing
This early-stage study tests a treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC